Literature DB >> 19824991

A retrospective evaluation of the impact of total smoking cessation on psychiatric inpatients taking clozapine.

I Cormac1, A Brown, S Creasey, M Ferriter, B Huckstep.   

Abstract

OBJECTIVE: To investigate the effect of a complete smoking ban on a group of psychiatric inpatients maintained on the antipsychotic medication clozapine.
METHOD: Retrospective data on clozapine dose and plasma levels were collected from a three month period before and a six month period after the introduction of the smoking ban.
RESULTS: Before the ban only 4.2% of patients who smoked had a plasma clozapine level > or =1000 microg/l but after the ban this increased to 41.7% of the sample within the six month period following the ban despite dose reductions.
CONCLUSION: Abrupt cessation of smoking is associated with a potentially serious risk of toxicity in patients taking clozapine. Plasma clozapine levels must be monitored closely and adjustments made in dosage, if necessary, for at least six months after cessation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19824991     DOI: 10.1111/j.1600-0447.2009.01482.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  12 in total

1.  Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level.

Authors:  Marc De Hert; Dan Cohen; Julio Bobes; Marcelo Cetkovich-Bakmas; Stefan Leucht; David M Ndetei; John W Newcomer; Richard Uwakwe; Itsuo Asai; Hans-Jurgen Möller; Shiv Gautam; Johan Detraux; Christoph U Correll
Journal:  World Psychiatry       Date:  2011-06       Impact factor: 49.548

2.  Predictors of smoking reduction outcomes in a sample of 287 patients with schizophrenia spectrum disorders.

Authors:  Bo-Jian Wu; Tsuo-Hung Lan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-27       Impact factor: 5.270

Review 3.  Clinically significant drug interactions with atypical antipsychotics.

Authors:  William Klugh Kennedy; Michael W Jann; Eric C Kutscher
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

Review 4.  Clinical Predictors of Response to Clozapine in Patients with Treatment Resistant Schizophrenia.

Authors:  Rajkumar A P; Chitra C; Bhuvaneshwari S; Poonkuzhali B; Kuruvilla A; Jacob K S
Journal:  Psychopharmacol Bull       Date:  2011-09-15

5.  A Reasonable Alternative to Clozapine in the Chronically Relapsing Smoking Patient? A Retrospective Analysis.

Authors:  John R Tomko; Nadeem Ahmed; Cynthia Kuntz; Justine Zick
Journal:  Hosp Pharm       Date:  2016-11

Review 6.  Clozapine in primary care.

Authors:  Karl Winckel; Dan Siskind
Journal:  Aust Prescr       Date:  2017-12-04

Review 7.  Factors associated with response to clozapine in schizophrenia: a review.

Authors:  Takefumi Suzuki; Hiroyuki Uchida; Koichiro Watanabe; Haruo Kashima
Journal:  Psychopharmacol Bull       Date:  2011

8.  Patient Management and Psychopharmacological Treatment Associated to Smoking Ban in an Acute Psychiatric Unit.

Authors:  Daniel Bergé; Anna Mané; Francina Fonseca; Alba Toll; Ana Merino; Victor Pérez; Antoni Bulbena
Journal:  Community Ment Health J       Date:  2014-12-24

9.  Effects of a smoking ban on clozapine plasma concentrations in a nonsecure psychiatric unit.

Authors:  Siobhan H Gee; David M Taylor; Sukhwinder S Shergill; Robert Flanagan; James H MacCabe
Journal:  Ther Adv Psychopharmacol       Date:  2016-12-02

10.  Electronic cigarettes in mental health settings - solving a conundrum?

Authors:  Elena Ratschen
Journal:  Psychiatr Bull (2014)       Date:  2014-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.